Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of HDM1005 versus tirzepatide in obese adults without diabetes
CTR20260925Phase 2Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of poterepatide, tirzepatide in obesity, Overweight, sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Mar 2026; status: active.
02
Drugs
poterepatidetirzepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20260925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260925.